A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer

BJU Int. 2019 Nov:124 Suppl 1:31-36. doi: 10.1111/bju.14773. Epub 2019 Sep 5.

Abstract

Objective: To characterize national clinical practice trends in the treatment of prostate cancer (PCa) in Australia.

Patients and methods: Population-level data were extracted from existing Medicare Benefits Schedule data for radical prostatectomy (RP) and brachytherapy (2002-2016), as well as external beam radiotherapy (EBRT; 2012-2016). Treatment rates were calculated relative to whole and PCa populations among privately treated patients. Overall age-related and geographical trends were analysed.

Results: The use of RP and low-dose-rate (LDR) brachytherapy increased between 2002 and 2009, but subsequently decreased to 124 and 6.9 per 100 000 men, respectively, in 2016. More dramatic decreases were observed for men aged <65 years. From 2012, rates of RP (15% drop) and LDR brachytherapy (58% drop) decreased, while the use of EBRT remained steady, falling by 5% to 42 per 100 000 men in 2016. Overall treatment increased in the age group 75-84 years, with the rate of RP increasing by 108%.

Conclusion: National claims data indicate there has been a reduction in PCa treatment since 2009, which is mostly attributable to a reduction in the treatment of younger patients and reduced use of brachytherapy. RP is most commonly used and its use is rising in men aged >65 years.

Keywords: #PCSM; #ProstateCancer; physicians; practice patterns; prostatectomy; prostatic neoplasms; radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • Australia / epidemiology
  • Brachytherapy / statistics & numerical data*
  • Combined Modality Therapy
  • Health Care Surveys
  • Humans
  • Insurance Claim Review / statistics & numerical data*
  • Male
  • Middle Aged
  • National Health Programs
  • Prostatectomy / statistics & numerical data*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Radiotherapy Dosage
  • Treatment Outcome

Substances

  • Androgen Antagonists